Ascletis’s Phase II Obesity Data Support Monthly Or Longer Dosing For ASC30

 
• By Joseph Haas
  
Newspaper cutouts of obesity keywords
Ascletis's GLP-1 may compete on durability of effect, less frequent dosing (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D